| |
Newsroom /
Health and Fitness
/
Health and Fitness
/
Canada Oral Antidiabetics Market to Reach Sales Worth US$ 406 Million by 2016
Canada Oral Antidiabetics Market to Reach Sales Worth US$ 406 Million by 2016
A new report from IMARC Group expects a strong uptake of DPP-IV Inhibitors to drive sales in the Canadian Oral Antidiabetics market during 2011-2016
Noida,
Uttar pardesh,
India
(prbd.net)
03/10/2011
In its new report entitled “Canada Diabetes Market Report & Forecast 2011-2016”, IMARC Group, one of the world’s leading providers of life science market intelligence expects the Canadian Oral Antidiabetics market to reach revenues worth US$ 406 Million by 2016. The report provides both current and future trends in the prevalence and demographical breakup of diabetes in Canada. The report has segmented the Canada diabetes market into two segments – Insulin and the Oral Antidiabetics market. For each of the aforementioned categories, the report provides historical and future market sales of key classes, key companies, key drugs and key molecules.
The research study serves as an exceptional tool to understand the market trends, therapeutic structure, competitive structure and the outlook of the Canadian diabetes market till 2016. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Canadian diabetes market in some form or the other.
Key Questions Answered in this Report:
• What is the size and demographical breakup of the diabetes population in Canada?
• How has the diabetes market behaved since 2005 and what are the expected trends till 2016?
• What has been the historical performance of the Canadian Insulin market during 2005-2010 and its outlook till 2016?
• What has been the performance of top classes, top players, top molecules and top drugs in the Insulin market during 2005-2010?
• What has been the historical performance of the Oral Antidiabetics market during 2005-2010 and its outlook till 2016?
• What has been the performance of top classes, top players, top molecules and top drugs in the Oral Antidiabetics market during 2005-2010?
Why should you buy this report?
• Gain a deeper understanding about the prevalence of diabetes in Canada and identify your potential patient pool.
• Analyze the historical, current and future trends in the Insulin market and identify potential classes, drugs, partners and competitors for market entry and expansion plans.
• Develop Investment strategies by identifying companies that have been the biggest winners and losers in the Canadian Insulin and Oral Antidiabetics market.
• Gain an insight into future market events such as biosimilars and new product launches.
Classes Covered
Oral Antidiabetics
Fast acting Insulin, Long acting Insulin, Intermediate and Fast acting Insulin, Intermediate acting Insulin, Biguanides, Glitazone and Biguanide Combinations, Biguanide and Sulphonylurea Combinations, Glinides, Sulphonylureas, Glitazones, DPP-IV Inhibitors, Glp-1 Agonists, Alpha-Glucosidase Inhibitors, DPP-IV Inhibitor and Biguanide Combinations, Glitazone and Sulphonylurea Combinations and all other Oral Antidiabetic classes.
Information Sources: Information has been sourced from both primary and secondary sources:
• Primary sources include industry surveys and face to face/telephone interviews with physicians and industry experts.
• Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, Industry Portals, government sources and access to more than 4000 paid databases.
Forecasting Methodology: IMARC generates its product and market forecasts utilizing its extensive database of macroeconomic and sector specific data. The initial baseline forecast is generated with the most recent market data. After an initial baseline forecast, all future macroeconomic and sector specific events and assumptions are taken into account to generate the final forecast.
Table of Contents
1 Executive Summary
2 Epidemiology
2.1 Total Diabetes Patients
2.2 Patients by Gender
2.3 Patients by Age Group
3 Market Dynamics
3.1 Diabetes Market
3.1.1 Current Trends (2005–2010)
3.1.2 Market Forecast (2011-2016)
3.2 Insulin Market
3.2.1 Current Trends (2005-2010)
3.2.1.1 Market by Class
3.2.1.2 Market by Molecule
3.2.1.3 Top Players
3.2.1.4 Top Drugs
3.2.2 Market Forecast (2011-2016)
3.3 Oral Antidiabetics
3.3.1 Current Trends (2005-2010)
3.3.1.1 Market by Class
3.3.1.2 Top Players
3.3.1.3 Top Drugs
3.3.2 Market Forecast (2011-2016)
To buy the complete report or to get a free sample:
Call: +91-120-425-6531 (Asia), +44-844-774-3860 (Europe), +1-631-791-1145 (America)
Email: sales@imarcgroup.com
For more information please visit: www.imarcgroup.com
About
For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
|